A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.

Trial Details

NCT ID
NCT06860971
Phase
PHASE3
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
RECRUITING
Cancer Type
Thyroid Cancer
Interventions
  • AL2846 Capsules
  • AL2846 Placebo
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Lanzhou, Gansu, China|36.05701,103.83987

Key Eligibility Criteria

  • Participants voluntarily join the study, sign the informed consent form, and demonstrate good compliance.
  • Histologically or cytologically confirmed locally advanced or metastatic differentiated thyroid carcinoma (DTC).
  • Age: 18 years ≤ age \<75 years (calculated based on the date of signing the informed consent form).
  • Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →